We are determined to realize the
promise of precision medicine.

HI-Bio™ was founded on the idea that therapies for immune-mediated diseases (IMDs) have the potential to achieve better results for patients.

Many IMDs stem from the dysfunction of cells that make up the immune system, including plasma cells, neutrophils, mast cells and more. These cells are responsible for critical functions and processes. HI-Bio’s programs apply a precision medicine approach to target, modulate or deplete these cellular drivers of disease with therapeutics.

HI-Bio is applying a precision medicine approach. Now is the time for medicines that use genetic and immunological insights to transform the lives of patients with severe IMDs.

HI-Bio became a Biogen company in 2024.